Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

Similar articles for PubMed (Select 23760942)

1.

High serum CA19-9 levels are associated with an increased risk of cholangiocarcinoma in patients with intrahepatic duct stones: a case-control study.

Jo JH, Chung MJ, Park JY, Bang S, Park SW, Kim KS, Lee WJ, Song SY, Chung JB.

Surg Endosc. 2013 Nov;27(11):4210-6. doi: 10.1007/s00464-013-3025-1. Epub 2013 Jun 13.

PMID:
23760942
2.

A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.

Hultcrantz R, Olsson R, Danielsson A, Järnerot G, Lööf L, Ryden BO, Wahren B, Broomé U.

J Hepatol. 1999 Apr;30(4):669-73.

PMID:
10207809
3.

Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis.

Kim YT, Byun JS, Kim J, Jang YH, Lee WJ, Ryu JK, Kim SW, Yoon YB, Kim CY.

Hepatogastroenterology. 2003 Jan-Feb;50(49):8-12.

PMID:
12629979
4.

Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level.

Kashihara T, Ohki A, Kobayashi T, Sato T, Nishizawa H, Ogawa K, Tako H, Kawakami F, Tsuji M, Tamaoka K.

J Gastroenterol. 1998 Jun;33(3):447-53.

PMID:
9658330
5.

Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma.

Kondo N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Sasaki H, Sueda T.

J Surg Oncol. 2014 Sep;110(4):422-9. doi: 10.1002/jso.23666. Epub 2014 Jun 2.

PMID:
24889968
6.

Intrahepatic cholangiocarcinoma associated with intrahepatic duct stones.

Hur H, Park IY, Sung GY, Lee DS, Kim W, Won JM.

Asian J Surg. 2009 Jan;32(1):7-12. doi: 10.1016/S1015-9584(09)60002-6.

PMID:
19321396
7.

Clinicopathologic spectrum of resected extraductal mass-forming intrahepatic cholangiocarcinoma.

Yamanaka N, Okamoto E, Ando T, Oriyama T, Fujimoto J, Furukawa K, Tanaka T, Tanaka W, Nishigami T.

Cancer. 1995 Dec 15;76(12):2449-56.

PMID:
8625070
8.

The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma.

Singh S, Tang SJ, Sreenarasimhaiah J, Lara LF, Siddiqui A.

Dig Dis Sci. 2011 Aug;56(8):2491-6. doi: 10.1007/s10620-011-1709-8. Epub 2011 Apr 23.

PMID:
21516323
9.

Risk factors of intrahepatic cholangiocarcinoma in patients with hepatolithiasis: a case-control study.

Liu ZY, Zhou YM, Shi LH, Yin ZF.

Hepatobiliary Pancreat Dis Int. 2011 Dec;10(6):626-31.

10.

Tumor markers as a diagnostic key for hilar cholangiocarcinoma.

Juntermanns B, Radunz S, Heuer M, Hertel S, Reis H, Neuhaus JP, Vernadakis S, Trarbach T, Paul A, Kaiser GM.

Eur J Med Res. 2010 Aug 20;15(8):357-61.

11.

CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation.

Fisher A, Theise ND, Min A, Mor E, Emre S, Pearl A, Schwartz ME, Miller CM, Sheiner PA.

Liver Transpl Surg. 1995 Mar;1(2):94-8.

PMID:
9346547
12.

Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.

Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N.

J Hepatobiliary Pancreat Surg. 2006;13(6):537-42. Epub 2006 Nov 30.

PMID:
17139428
13.

Comparison of concomitant and subsequent cholangiocarcinomas associated with hepatolithiasis: Clinical implications.

Lin CC, Lin PY, Chen YL.

World J Gastroenterol. 2013 Jan 21;19(3):375-80. doi: 10.3748/wjg.v19.i3.375.

14.

Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.

Leelawat K, Sakchinabut S, Narong S, Wannaprasert J.

BMC Gastroenterol. 2009 Apr 30;9:30. doi: 10.1186/1471-230X-9-30.

15.

Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma.

Liu L, Wang J, Liu B, Dai S, Wang X, Chen J, Huang L, Xiao X, He D.

J Cell Biochem. 2008 Jun 1;104(3):745-55. doi: 10.1002/jcb.21661.

PMID:
18275060
16.

Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.

Lempinen M, Isoniemi H, Mäkisalo H, Nordin A, Halme L, Arola J, Höckerstedt K, Stenman UH.

J Hepatol. 2007 Nov;47(5):677-83. Epub 2007 Jun 27.

PMID:
17640760
17.

Astronomically high CA 19-9 in a patient with a benign lesion.

Rao NA, Satyaprakash BS.

S Afr J Surg. 2013 Oct 29;51(4):151. doi: 10.7196/sajs.1813. No abstract available.

PMID:
24209706
18.

Etiological and clinicopathologic characteristics of intrahepatic cholangiocarcinoma in young patients.

Zhou HB, Wang H, Zhou DX, Wang H, Wang Q, Zou SS, Hu HP.

World J Gastroenterol. 2010 Feb 21;16(7):881-5.

19.

Hepatolithiasis associated with cholangiocarcinoma.

Su CH, Shyr YM, Lui WY, P'Eng FK.

Br J Surg. 1997 Jul;84(7):969-73.

PMID:
9240138
20.

Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA.

Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR.

World J Gastroenterol. 2004 Feb 1;10(3):427-32.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk